ClinicalTrials.gg
CompletedNCT03763136HEAL-CHFUpdated Aug 22, 2025

Treating Heart Failure With hPSC-CMs

A Phase 1/2 interventional study of hPSC-CM Therapy in Heart Failure, sponsored by HELP Therapeutics Co., Ltd.. Completed at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by HELP Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Enrollment
224th of 247
20 · median 130
Started
2021
with 30 others
Phase 1/2
14 of 377
7 open now
Registered
104th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 224th largest by enrollment of the 247 interventional ones that give a count, is one of 31 that started in 2021, is one of 14 in phase 1/2, and was the 104th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes. Cellular replacement therapy is a potential approach to repair damaged myocardial tissue, restore cardiac function, which has become a new strategy for the treatment of heart failure. The purpose of this study is to assess the safety, feasibility and efficacy of intramyocardial delivery of cardiomyocytes at the time of coronary artery bypass grafting in patients with chronic heart failure.

Read the detailed description

Patients with heart failure will be treated with allogenic human pluripotent stem cell-derived cardiomyocytes ( hPSC-CM ) from healthy donors. The cells will be injected directly into the myocardium at time of coronary artery bypass grafting. Patients will be assessed at 1, 6 and 12 months after cell transplantation for safety, feasibility and efficacy.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 35-75 (including 35 and 75).
  2. Have signed the Form (ICF).
  3. Patients have chronic left ventricular dysfunction.
  4. Patients have Class III-IV cardiac function even after improved medication for the treatment of advanced chronic heart failure.
  5. Patients have indications for Coronary Artery Bypass Grafting.
  6. 20% ≤ ≤ 45% as determined by echocardiogram (data collected up to 6 months prior to inclusion evaluation are valid; data collected within 1 month since a myocardial infarction are invalid).
  7. Weakening or absence of segmental regional wall motion as determined by standard imaging.

Exclusion criteria

Exclusion criteria

  1. PRA ≥ 20% or DSA-positive.
  2. Patient received ICD transplantation, CRT or similar treatment.
  3. Patients with valvular heart disease or received heart valvular disease
  4. Patients received treatment of percutaneous transluminal coronary intervention (PCI)
  5. Patients with atrial fibrillation
  6. Patients previously suffered sustained ventricular tachycardia or sudden cardiac death.
  7. Baseline \<30ml/min/1.73m2.
  8. Liver dysfunction, as evidenced by enzymes ( and ALT) greater than three times the .
  9. Hematological abnormality: A hematocrit \<25% as determined by HCT, white blood cell\<2500/ul or values \<100000/ul without another explanation.
  10. Known, serious radiographic contrast allergy, penicillin allergy, streptomycin allergy.
  11. Coagulopathy (>1.3) not due to a reversible cause.
  12. to performance of a MRI scan.
  13. Recipients of organ transplant.
  14. Clinical history of within 5 years (patients with prior malignancy must be disease free for 5 years).
  15. Non-cardiac condition that limits lifespan \<1 year.
  16. On chronic therapy with medication, such as and TNFα antagonist.
  17. Patients allergy to or cannot use immunosuppressant.
  18. Serum positive for , , , TP.
  19. Currently enrolled other therapeutic or device study.
  20. Patients who are pregnant or breast feeding.
  21. Other conditions that researchers consider not suitable to participate in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    hPSC-CM Therapy

    Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.

    Biological: hPSC-CM Therapy

  • Sham comparator
    Control

    Procedure: Coronary artery bypass grafting surgery only.

    Biological: hPSC-CM Therapy

Interventions

  • BiologicalhPSC-CM Therapy

    Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.

06

What researchers measure

Primary outcomes

  1. Incidence of sustained ventricular arrhythmias

    defined as the proportion of patients experiencing ventricular arrhythmias lasting more than 30 seconds

    Time frame: 1~6 Month Post-operation

  2. Incidence of newly formed tumors

    by comparing chest, abdominal and pelvic CT scan and PET-CT scan

    Time frame: 1~12 Month Post-operation

Secondary outcomes

  1. Overall Left Ventricular systolic performance as assessed by MRI

    Size of infracted myocardium, left ventricular side wall thickness at diastolic, interventricular septum thickness, left ventricular ejection fraction, left ventricular end-systolic volume and end-diastolic volume, stroke volume, cardiac output, myocardium density and left ventricular mass at diastolic will be evaluated and compared to baseline values.

    Time frame: Baseline, 6 and 12 Months Post-operation

  2. Overall Left Ventricular systolic performance as assessed by Echocardiogram

    Interventricular septum thickness at diastolic, left ventricular end-systolic diameter and end-diastolic diameter, left ventricular posterior wall thickness at diastolic, left atrial diameter, left ventricular ejection fraction, mitral flow pattern (E/A) will be evaluated and compared to baseline values.

    Time frame: Baseline, 6 and 12 Months Post-operation

  3. Overall Left Ventricular systolic performance as assessed by PET/ECT Scan

    Myocardium perfusion

    Time frame: Baseline, 6 and 12 Months Post-operation

  4. Functional status by 6 minute walk test

    Evaluate Functional Capacity via the Six Minute Walk Test

    Time frame: Baseline, 6 and 12 Months Post-operation

  5. Functional status by New York Heart Association (NYHA) Classification

    Evaluate Functional Capacity via New York Heart Association (NYHA) Class Determination

    Time frame: Baseline, 6 and 12 Months Post-operation

  6. Minnesota Living With Heart Failure Questionnaire (MLHFQ)

    Evaluate Quality Of Life Changes via Minnesota Living with Heart Failure (MLHF). The Maximum possible scores being 105 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life.

    Time frame: Baseline, 1, 6 and 12 Months Post-operation

  7. Incidence of Major Adverse Cardiac Events (MACE)

    Major Adverse Cardiac Events (MACE), defined as the composite incidence of (1) death, (2) non-lethal myocardial infraction, and (3) hospitalization for worsening HF

    Time frame: Baseline, 1~12 Months Post-operation

  8. Incidence of Serious Adverse Events (SAE)

    SAE justified (all undesirable or unintended diseases or laboratory and imaging disorders and symptoms that occur in subjects after CABG surgery and 12 months postoperative follow-up, or until the subject withdrawals from the study. AE grading will be based on Common Terminology Criteria for Adverse Events (CTCAE) V5.0.)

    Time frame: Baseline, 1~12 Months Post-operation

  9. Changes in penal reactive antibodies (PRA)

    Changes in penal reactive antibodies (PRA) as assessed via blooddraw

    Time frame: Baseline, 1, 6 and 12 Months Post-operation

  10. Changes in donor specific antibodies (DSA)

    Changes in donor specific antibodies (DSA) as assessed via blooddraw

    Time frame: Baseline, 1, 6 and 12 Months Post-operation

  11. Incidence of severe arrhythmia

    Clinically significant arrhythmias will be recorded by Electrocardiogram monitoring

    Time frame: First month post-operatively

  12. Changes in cytokines

    Change in NT-proBNP as assessed via blooddraw

    Time frame: Baseline,1, 6 and 12 Months Post-operation

07

Study locations

1 site
  • HelpThera
    Nanjing, Jiangsu 210000, China
08

References and documents

Publications

  • Zhang H, Xue Y, Pan T, Zhu X, Chong H, Xu C, Fan F, Cao H, Zhang B, Pan J, Zhou Q, Yang G, Wang J, Wang DJ. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open. 2022 May 6;12(5):e056264. doi: 10.1136/bmjopen-2021-056264. PubMed 35523485 ↗

Individual participant data

Plan to share: Yes — Results of the trial will be disseminated to study participants through direct consultation with a trial clinician at completion of the trial, as well as through the publication of results.

Supporting information: Study protocol, Clinical study report

Time frame: One year after study completed

Access criteria: Results of the trial will be disseminated to study participants through direct consultation with a trial clinician at completion of the trial, as well as through the publication of results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Apr 2024, 30 months.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Dec 4, 2018
StartActual
Oct 8, 2021
Primary completionActual
Apr 30, 2024
CompletionActual
Oct 30, 2024
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03763136
Lead sponsor
HELP Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2018
Start date
Oct 8, 2021
Primary completion
Apr 30, 2024
Completion
Oct 30, 2024
Last update
Aug 22, 2025

Study contacts

Dongjin Wang, MD
principal investigator · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion